Temsirolimus
Temsirolimus is a pharmaceutical drug with 169 clinical trials. Currently 13 active trials ongoing. Historical success rate of 80.7%.
Success Metrics
Based on 117 completed trials
Phase Distribution
Phase Distribution
84
Early Stage
71
Mid Stage
6
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
77.5%
117 of 151 finished
22.5%
34 ended early
13
trials recruiting
169
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma
Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer
Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer
Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer
Clinical Trials (169)
Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma
Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer
Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer
Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG
Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer
Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours
Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)
Temsirolimus and Cetuximab in Patients With Advanced or Metastatic Solid Tumors
Dasatinib, Temsirolimus, and Cyclophosphamide in Treating Patients With Advanced, Recurrent, or Refractory Solid Tumors
Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors
Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma
Torisel in Addition to Standard Chemotherapy With Radiation for Advanced Head and Neck Cancer
Temsirolimus Adventitial Delivery to Improve ANGioplasty and/or Atherectomy Revascularization Outcomes Below the Knee
Vorinostat and Temsirolimus With or Without Radiation Therapy in Treating Younger Patients With Newly Diagnosed or Progressive Diffuse Intrinsic Pontine Glioma
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 169